LOGIN
Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis
October 2013
Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
One hundred women with osteoporosis were evaluated to compare the efficacy of teriparatide, denosumab, or combined treatment of both drugs on spinal, femoral, and hip bone mineral density (BMD) at 12 months. They were randomized either to daily 20 ug teriparatide daily, 60 mg denosumab every 6 months, or both. At the final follow up, the combination group had increased significantly in posterioran...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.